Astrazeneca Ab

Dizal (jiangsu) Pharmaceutical Co., Ltd.

Dizal Pharmaceutical Co., Limited

Wenzhan Yang

Jason Grant Kettle

Dedong Wu

Daniel T Robbins

Michelle Lamb

Alexander Hird

Jeffrey Wallace Johannes

Xiaolan Zheng

Qibin Su

Claudio Edmundo Chuaqui

Bo Peng

Neil Patrick Grimster

Steven Kazmirski

Qing Ye

Richard Donald Woessner

Jon James Winter-Holt

Matthew Belmonte

Paul Secrist

James Mccabe

Tudor Grecu

Annika Birgitta Margareta ÅStrand

Magnus K Nilsson

Linette Lys Ruston

Melissa Marie Vasbinder

Steven Lee Kazmirski

Michelle Laurae Lamb

Matthew Alan Belmonte

Daniel William Robbins

Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein

Compounds and methods for inhibiting JAK

Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.10000]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.10000]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.

Mcl-1 inhibitors and methods of use thereof

Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.10,000]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.10000]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.

MCL-1 inhibitors and methods of use thereof

Growing community of inventors

Waltham, MA, United States of America

Wenzhan Yang